Sarepta Therapeutics, Inc.
Exon skipping oligomer conjugates for muscular dystrophy

Last updated:

Abstract:

Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.

Status:
Grant
Type:

Utility

Filling date:

14 Dec 2017

Issue date:

12 Jul 2022